Tag Archives: antioxidant
Just published… a key study looking at the effect of antioxidant supplementation with vitamin C, vitamin E, coenzyme Q10 and selenium on arterial health and inflammation. As the research gathers pace, heart disease and the clogging of the arteries known as atherosclerosis is being view more as an inflammatory disease rather than a passive accumulation of fatty material within the walls of blood vessels.
This latest paper helps support the long held theory that antioxidants can help off set this process and protect the health of the cardiovascular system.
In this study, 70 people with two diagnosed cardiovascular risk factors (see the study for details) were recruited from a hypertension clinic. 35 people were given a 6 month course of capsules containing vitamin C (500 mg) vitamin E (200 iu), co- enzyme Q10 (60 mg) and selenium (100 mcg) while the other 35 were given a placebo. The summary conclusion is displayed below and the results and technicalities can be viewed by following the link at the end of this post.
Conclusions: Antioxidant supplementation significantly increased large and small artery elasticity in patients with multiple cardiovascular risk factors. This beneficial vascular effect was associated with an improvement in glucose and lipid metabolism as well as decrease in blood pressure.
The original paper is free to download from the open access journal by clicking here.
Shargorodsky M, Debbi O, Matas, Z, Zimlichman R. Effect of long term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Nutrition & Metabolism 2010, 7:55 doi: 10.1186/1743-7075-7-55
If you are a co-enzyme Q10 user – read on… We have a special but limited supply of Smart Q10 that is being offered on a but-1-get-1-FREE deal. This is a genuinely unique product and to our knowledge, the only Q10 product that can boast that 21 studies in support of its use.See April 28th blog entry for a list of these studies.
Q10, also referred to as coenzyme Q 10 or ubiquinone, is a natural fat-soluble nutrient present in virtually all living cells in the body. CoQ10 has a crucial role as a cofactor in the mitochondrial synthesis of cellular energy. Although it is produced by the body and exists in some dietary sources, these levels may be insufficient to meet the body’s requirement.
- Matthews RT, Yang L, Browne S, Baik MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998; 95:8892-8897.
- Langsjoen P. Overview of the use of CoQ10 in cardiovascular disease. Presented at The First Conference of the International Coenzyme Q10 Association. Boston, Mass, May 21-24, 1998.
- Koroshetz W. Huntington’s Disease Clinical Trail. Presented at the First Conference of the International Coenzyme Q10 Association. Boston. Mass, May 21-24, 1998.
- Shults CW, Haas RH, Flint Beal M. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. Proceedings of First Conference of the International Coenzyme Q10 Association, 95:8892-8897, July 21, 1998.
- Beal MF. Coenzyme Q10 as a potential treatment for neurodegenerative diseases. Presented at the First Conference of the International Coenzyme Q10 Association. Boston. Mass, May 21-24, 1998.
- Beal MF. Energy impairment and Huntington’s disease. Presented at the Mitochondrial Medicine Conference. University of California, San Diego School of Medicine, Mitochondrial and Metabolic Disease Center, San Diego, Calif, Feb 19-21, 1998.
- Kieburtz K, Rickey T. Co-enzyme Q10 and remacemide: evaluation in Huntington¡¦s disease (CARE-HD). A controlled investigation by the Huntington Study Group. Clinical trial in progress. Institutions participating in the CARE-HD Study: Allegheny University, Baylor College of Medicine, Boston University, Bowman Gray School of Medicine, Colorado Neurological Institute, Columbia-Presbyterian, Emory University, Indiana School of Medicine, Johns Hopkins University, Massachusetts General Hospital, Rush-Presbyterian-St.Luke’s Medical Center, Tampa General Hospital, and the universities of Alberta, British Columbia, Calgary, Iowa, Kansas Medical Center, Miami School of Medicine, Michigan, Rochester, Toronto, and Virginia. June 1997-2002.
- Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med. 1997;18:S145-S151.
- Shults CW, Flint Beal MD, Fontaine D, Nakeno K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 1998;50:793-795.
- Flint Beal M, Matthews RT, Tielman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetradopyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783:109-114.
- Flint Beal M, Matthews RT. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative disease. Mol Aspects Med. 1997;18:S169-S179.
- Schwid SR, Mattson DH, Goodman AD. A phase II trial of coenzyme Q10 in MS. Clinical trial in progress. University of Rochester, Department of Neurology, Neuroimmunology Unit, Rochester, New York. 1996-2000.
- Koroshetz W. Huntington’s Disease Clinical Trail. Presented at the First Conference of the International Coenzyme Q10 Association. Boston, Mass, May 21-24, 1998.
- Shults CW, Haas RH, Passov D, Flint Beal M Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42:261-264.
- Feigin A, Kieburtz K, Como C, et al. Assessment of coenzyme Q10 tolerability in Huntington’s disease. Mov Disord. 1996;11:321-323.
- Cros D. Amyotrophic Lateral Sclerosis (ALS). Harvard Medical School- Massachusetts General Hospital Department of Neurology EMG Unit-Bigelow 12, Boston, Mass, 1995-1998.
- Tardive Dyskinesia Study Using Coenzyme Q10 and Nicotinamide. Harvard Medical School-Massachusetts General Hospital Department of Psychiatry and Neurology, Freedom Trial Clinic, Erich Lindemann Mental Health Center, Boston, Mass, 1995.
- Costeff H. CoQ10 and 3-Methylglutaconic Aciduria. Neuropediatric Unit. Loewenstein Hospital Rehabilitation Center, Tel Aviv. Medical School, Raanana, Israel, 1998.
- Flint Beal. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 1996;71:1043-1048.
- Flint Beal M, Henshaw R, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994;36:882-888.
- Schulz JB, Henshaw RD, Matthews RT, Flint Beal M. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995;132:279-283.